Supply of the product Elevit with Iodine film-coated tablet

Overview

The Therapeutic Goods Act 1989 was enacted to provide a legal framework for the regulation of therapeutic goods, including medicines, medical devices, and blood, in Australia. The Act was introduced to address the need for a comprehensive system to ensure that therapeutic goods are safe, of high quality, and effective. The Therapeutic Goods Administration (TGA), which operates under the Department of Health, is the body responsible for administering the Act. The primary policy objective of the Act is to protect public health by regulating the supply and advertising of therapeutic goods in Australia. In May 2014, under the authority granted by the Act, the delegate of the Secretary of the Department of Health granted a specific consent for the importation and supply of Elevit with Iodine film-coated tablets that did not fully comply with certain standards set out in the Therapeutic Goods Order No. 78. This consent was issued to address an immediate public health need, allowing the supply of these specific batches of the product under certain conditions to ensure the content of active ingredients met specified limits. This action underscores the TGA's role in balancing regulatory compliance with public health considerations when necessary.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration within the Department of Health, governs the regulation of therapeutic goods in Australia, including the importation and supply of such goods. Under sections 14 and 14A of the Act, the Secretary's delegate has the authority to grant consent for the importation and supply of therapeutic goods that do not conform to specific standards, as evidenced by the recent consent for the importation of Elevit with Iodine film-coated tablets. This consent applies to specified batches only up until 31 July 2014, and is subject to certain conditions, such as compliance with the content limits of active ingredients. The consent does not specify a broad application to all non-conforming goods but is narrowly tailored to particular batches of Elevit with Iodine film-coated tablets, demonstrating the Act's ability to address specific regulatory concerns on a case-by-case basis. The jurisdictional reach of the Therapeutic Goods Act 1989 is national, with the Act applying to all therapeutic goods within Australia, encompassing a wide range of entities and industries involved in the production, importation, supply, and advertising of therapeutic goods.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) includes specific provisions under sections 14 and 14A that allow the Secretary's delegate to provide consent for the importation and supply of therapeutic goods that do not fully conform to certain standards. In this instance, the delegate granted consent for the import and supply of Elevit with Iodine film-coated tablets AUST R 174543 (sections 14 and 14A). This consent pertains to particular batches of these tablets and is valid only until 31 July 2014 (section 15(1)). The non-conforming elements of these tablets relate to the requirements of sections 11(b) and 11(c) of Therapeutic Goods Order No. 78 (TGO 78), which sets out the standard for tablets and capsules. The consent comes with conditions to ensure the safety and quality of the therapeutic goods. Specifically, the content of the 18 active ingredients in Elevit with Iodine film-coated tablets AUST R 174543 must comply with specified limits (section 15(1)). These limits are detailed in a table provided in the consent, ensuring that the levels of each active ingredient fall within a defined percentage range of the standard. Entities involved in the import and supply of these tablets must ensure compliance with these conditions. This includes verifying that the active ingredients are within the stipulated limits and maintaining records that demonstrate compliance. Failure to adhere to these conditions may result in serious consequences. The Act does not explicitly detail penalties for non-compliance in this context, but general provisions within the Act may apply, including potential fines and imprisonment for breaches that endanger public health. Understanding and complying with the specific conditions set forth in the consent is crucial for those involved in the distribution of these therapeutic goods. Non-compliance can lead to enforcement actions by the Therapeutic Goods Administration, which may include product recalls, fines, or other regulatory measures. It is imperative for parties to remain vigilant and proactive in ensuring adherence to the conditions to avoid any legal repercussions.